DNLI - Denali Therapeutics Inc.

20.37
0.350   1.718%

Share volume: 1,227,719
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$20.02
0.35
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 27%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.00%
1 Month
1.75%
3 Months
2.05%
6 Months
32.02%
1 Year
24.97%
2 Year
-0.39%
Key data
Stock price
$20.37
P/E Ratio 
0.00
DAY RANGE
$19.94 - $20.92
EPS 
-$2.97
52 WEEK RANGE
$10.57 - $23.77
52 WEEK CHANGE
$25.20
MARKET CAP 
2.421 B
YIELD 
N/A
SHARES OUTSTANDING 
158.591 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
2.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,454,519
AVERAGE 30 VOLUME 
$1,610,852
Company detail
CEO: Ryan J. Watts
Region: US
Website: denalitherapeutics.com
Employees: 430
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Recent news